An Intensified Regimen Containing Linezolid Could Improve Treatment Response in Mycobacterium abscessus Lung Disease

الملخص EN

Background.

Treatment response for the Mycobacterium abscessus (M.

abscessus) lung disease remains far from satisfying.

An effective regimen is needed to solve the problem.

Methods.

We retrospectively reviewed the medical records of all patients with M.

abscessus lung disease who received antibiotics regimen at Beijing Chest Hospital Affiliated to Capital Medical University between July 1, 2010, and February 1, 2018.

Patients were administered a conventional antibiotics regimen (including macrolide and moxifloxacin, along with an initial 12-week course of low-dose cefoxitin and amikacin) or intensified regimen (including a higher dosage of cefoxitin and linezolid besides conventional drugs), respectively.

The time to sputum-culture conversion and proportion of sputum-culture conversion in liquid broth were investigated to evaluate the efficacy and evaluation of safety by performing the classification of adverse events according to the Division of AIDS, National Institute of Allergy and Infectious Disease.

Patients were followed for 18 months from baseline.

Results.

In the conventional regimen group, the sputum conversion rate at 18 months was 29.4% (10/34), and the median time until sputum conversion was 2 months (IQR, 1-2 mo).

Furthermore, in the intensified regimen group, the sputum conversion rate was 81.3% (13/16), and the median time until sputum conversion was 1 month (IQR, 1-1 mo).

Leukopenia and drug-induced hepatotoxicity occurred more frequently in the intensified regimen group in contrast with the conventional regimen group patients.

However, only 1 adverse event in the intensified regimen group was classified as severe adverse event.

Conclusions.

The intensified regimen could improve sputum conversion of M.

abscessus lung disease compared with conventional regimen, but close safety surveillance is necessary to monitor adverse events.